Aequus Pharmaceuticals (CVE:AQS) Reaches New 12-Month Low – Should You Sell?

Aequus Pharmaceuticals Inc. (CVE:AQSGet Free Report)’s stock price reached a new 52-week low on Monday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 45000 shares changing hands. The stock had previously closed at C$0.01.

Aequus Pharmaceuticals Trading Down 50.0 %

The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07. The company has a market capitalization of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02. The firm has a fifty day moving average price of C$0.01 and a 200-day moving average price of C$0.02.

About Aequus Pharmaceuticals

(Get Free Report)

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.

See Also

Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.